MATERIALS AND METHODS FOR TREATING PATIENTS WITH TAXOXIFEN
    1.
    发明申请
    MATERIALS AND METHODS FOR TREATING PATIENTS WITH TAXOXIFEN 审中-公开
    用TAXOXIFEN治疗患者的材料和方法

    公开(公告)号:US20120088247A1

    公开(公告)日:2012-04-12

    申请号:US13202418

    申请日:2010-02-23

    IPC分类号: C12Q1/68

    摘要: A pathway for the metabolism of tamoxifen is identified including the activity of at least 2 different isoforms of UGY2B7. This pathway includes isozymes of CYP3A which convert tamoxifen (TAM) to N-desmethyl-TAM, which is then converted to endoxifen by the action of CYP2D6. Once formed, endoxifen may be degraded by at least one isozyme of UGT2B7. Patients that have highly active isoforms of CYP2D6 and slow acting isoforms of UGT2B7 accumulate high levels of endoxifen and are good candidates for treatment with tamoxifen. Also disclosed are methods for screening patients with a high likelihood of benefiting from treatment with tamoxifen. These methods include testing patients for various alleles of genes known to be involved in tamoxifen metabolism and treating patients accordingly.

    摘要翻译: 确定了他莫昔芬代谢途径,包括UGY2B7至少2种不同同种型的活性。 该途径包括将他莫昔芬(TAM)转化为N-去甲基-TAM的CYP3A同功酶,然后通过CYP2D6的作用将其转化为内毒素。 一旦形成,内皮素可能被UGT2B7的至少一种同功酶降解。 具有CYP2D6高活性同种型和UGT2B7慢作用亚型的患者积累高水平的内皮素,是治疗他莫昔芬的良好候选药物。 还公开了用于筛选可能受益于他莫昔芬治疗的患者的方法。 这些方法包括测试患者已知参与他莫昔芬代谢的基因的各种等位基因,并相应地治疗患者。

    METHOD AND COMPOSITION TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST
    2.
    发明申请
    METHOD AND COMPOSITION TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST 有权
    评估细胞色素P450 2C19的方法和组合使用通气测试的ISOENZYME活性

    公开(公告)号:US20080085240A1

    公开(公告)日:2008-04-10

    申请号:US11848750

    申请日:2007-08-31

    IPC分类号: A61K51/04 G01N33/00

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定和评估个体哺乳动物受试者中细胞色素P450 2C19相关(CYP2Cl9)代谢能力的方法,通过确定相对量 静脉内或口服施用13 C- C标记的CYP2C19底物化合物时,受试者呼出的> 2 。 本发明可用作非侵入式体内测定,用于使用呼吸道呼吸中的代谢物13评价受试者中CYP2C19酶活性,以表现个体受试者 并确定药物给药的选择,最佳剂量和时间。

    METHODS TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST
    3.
    发明申请
    METHODS TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST 审中-公开
    评估细胞色素P450 2C19使用呼吸试验的ISOENZYME活性的方法

    公开(公告)号:US20110111510A1

    公开(公告)日:2011-05-12

    申请号:US12942280

    申请日:2010-11-09

    IPC分类号: G01N37/00 C07D401/12

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2C19) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as anon-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定个体哺乳动物受试者的细胞色素P450 2C19相关(CYP2C19)代谢能力的方法,通过确定受试者在静脉内或口服给药后呼出的13CO2的相对量 13C标记的CYP2C19底物化合物。 本发明可用作用于评估受试者中使用呼吸道呼吸中代谢物13CO2的CYP2C19酶活性的非侵入式体内测定,以表现个体受试者并确定药物施用的选择,最佳剂量和时间。

    Methods to evaluate cytochrome P450 2C19 isoenzyme activity using a breath test
    4.
    发明授权
    Methods to evaluate cytochrome P450 2C19 isoenzyme activity using a breath test 有权
    使用呼吸试验评估细胞色素P450 2C19同工酶活性的方法

    公开(公告)号:US07833744B2

    公开(公告)日:2010-11-16

    申请号:US11848750

    申请日:2007-08-31

    IPC分类号: C12Q1/26

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定和评估个体哺乳动物受试者中细胞色素P450 2C19相关(CYP2Cl9)代谢能力的方法,通过确定受试者在静脉内或口服给药后呼出的13CO2的相对量 13C标记的CYP2C19底物化合物。 本发明可用作非侵入性体内测定,用于评估受试者中使用呼吸道呼吸中的代谢物13CO2,表型个体受试者的CYP2C19酶活性,并确定药物给药的选择,最佳剂量和时机。